Macrolide-resistant Streptococcus pyogenes: prevalence and treatment strategies

References

• Shaikh N, Leonard E, Martin JM. Prevalence of streptococcal pharyngitis and streptococcal carriage in children: a meta-analysis. Pediatrics 2010;126(3):e557-64
   PubMed Web of Science ®Google Scholar
• Bessen DE, Hollingshead SK. Molecular epidemiology, ecology, and evolution of group A streptococci. In: Fischetti VA, Novick RP, Ferretti JJ, Portnoy DA, Rood JI, editors. Gram positive pathogens. ASM Press; Washington, DC: 2006. p. 143-51
   Google Scholar
• Guy R, Williams C, Irvine N, et al. Increase in scarlet fever notifications in the United Kingdom, 2013/2014. Euro Surveill 2014;19(12):20749
   PubMedGoogle Scholar
• Luk EYY, Lo JYC, Li AZL, et al. Scarlet fever epidemic, Hong Kong, 2011. Emerg Infect Dis 2012;18(10):1658-61
   PubMed Web of Science ®Google Scholar
• Yang P, Peng X, Zhang D, et al. Characteristics of Group A Streptococcus strains circulating during scarlet fever epidemic, Beijing, China, 2011. Emerg Infect Dis 2013;19(6):909-15
   PubMed Web of Science ®Google Scholar
• Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissues. N Engl J Med 1996;334(4):240-5
   PubMed Web of Science ®Google Scholar
• Efstratiou A. Group A streptococci in the 1990s. J Antimicrob Chemother 2000;45(Suppl):3-12
   PubMed Web of Science ®Google Scholar
• Stevens DL. Streptococcal toxic shock syndrome associated with necrotizing fasciitis. Annu Rev Med 2000;51(1):271-88
   PubMed Web of Science ®Google Scholar
• Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev 2000;13(3):470-511
   PubMed Web of Science ®Google Scholar
• Lee JL, Naguwa SM, Cheema GS, Gershwin ME. Acute rheumatic fever and its consequences: a persistent threat to developing nations in the 21st century. Autoimmun Rev 2009;9(2):117-23
   PubMed Web of Science ®Google Scholar
• Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005;5(11):685-94
   PubMed Web of Science ®Google Scholar
• Jacobs MR, Johnson CE. Macrolide resistance: an increasing concern for treatment failure in children. Pediatr Infect Dis J 2003;22(8 Suppl):S131-8
   Web of Science ®Google Scholar
• Weisblum B. Macrolide resistance. Drug Resist Updat 1998;1(1):29-41
   PubMed Web of Science ®Google Scholar
• Tenson T, Lovmar M, Ehrenberg M. The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome. J Mol Biol 2003;330(5):1005-14
   PubMed Web of Science ®Google Scholar
• Douthwaite S, Champney WS. Structures of ketolides and macrolides determine their mode of interaction with the ribosomal target site. J Antimicrob Chemother 2001;48(Suppl 2):1-8
   PubMed Web of Science ®Google Scholar
• Champney WS, Tober CL. Specific inhibition of 50S ribosomal subunit formation in Staphylococcus aureus cells by 16-membered macrolide, lincosamide, and streptogramin B antibiotics. Curr Microbiol 2000;41(2):126-35
   PubMed Web of Science ®Google Scholar
• Weisblum B. Erythromycin resistance by ribosome modification. Antimicrob Agents Chemother 1995;39(3):577-85
   PubMed Web of Science ®Google Scholar
• Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis 2002;34(4):482-92
   PubMed Web of Science ®Google Scholar
• Weisblum B. Insights into erythromycin action from studies of its activity as inducer of resistance. Antimicrob Agents Chemother 1995;39(4):797-805
   PubMed Web of Science ®Google Scholar
• Varaldo PE, Montanari MP, Giovanetti E. Genetic elements responsible for erythromycin resistance in streptococci. Antimicrob Agents Chemother 2009;53(2):343-53
   PubMed Web of Science ®Google Scholar
• Roberts MC. Update on macrolide–lincosamide–streptogramin, ketolide, and oxazolidinone resistance genes. FEMS Microbiol Lett 2008;282(2):147-59
   PubMed Web of Science ®Google Scholar
• Giovanetti E, Brenciani A, Burioni R, Varaldo PE. A novel efflux system in inducibly erythromycin-resistant strains of Streptococcus pyogenes. Antimicrob Agents Chemother 2002;46(12):3750-5
   PubMed Web of Science ®Google Scholar
• Sutcliffe J, Tait-Kamradt A, Wondrack L. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob Agents Chemother 1996;40(8):1817-24
   PubMed Web of Science ®Google Scholar
• Del Grosso M, Camilli R, Barbabella G, et al. Genetic resistance elements carrying mef subclasses other than mef(A) in Streptococcus pyogenes. Antimicrob Agents Chemother 2011;55(7):3226-30
   PubMed Web of Science ®Google Scholar
• Figueiredo TA, Aguiar SI, Melo-Cristino J, Ramirez M. DNA methylase activity as a marker for the presence of a family of phage-like elements conferring efflux-mediated macrolide resistance in streptococci. Antimicrob Agents Chemother 2006;50(11):3689-94
   PubMed Web of Science ®Google Scholar
• Kataja J, Huovinen P, Group TMRS, Seppälä H. Erythromycin resistance genes in group A streptococci of different geographical origins. J Antimicrob Chemother 2000;46(5):789-92
   PubMed Web of Science ®Google Scholar
• Silva-Costa C, Ramirez M, Melo-Cristino J. Identification of macrolide-resistant clones of Streptococcus pyogenes in Portugal. Clin Microbiol Infect 2006;12(6):513-18
   PubMed Web of Science ®Google Scholar
• Bingen E, Leclercq R, Fitoussi F, et al. Emergence of group A Streptococcus strains with different mechanisms of macrolide resistance. Antimicrob Agents Chemother 2002;46(5):1199-203
   PubMed Web of Science ®Google Scholar
• Rubio-López V, Valdezate S, Álvarez D, et al. Molecular epidemiology, antimicrobial susceptibilities and resistance mechanisms of Streptococcus pyogenes isolates resistant to erythromycin and tetracycline in Spain (1994–2006). BMC Microbiol 2012;12:215
   PubMed Web of Science ®Google Scholar
• Pérez-Trallero E, Martín-Herrero JE, Mazón A, et al. Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007). Antimicrob Agents Chemother 2010;54(7):2953-9
   PubMed Web of Science ®Google Scholar
• Ardanuy C, Domenech A, Rolo D, et al. Molecular characterization of macrolide- and multidrug-resistant Streptococcus pyogenes isolated from adult patients in Barcelona, Spain (1993-2008). J Antimicrob Chemother 2010;65(4):634-43
   PubMed Web of Science ®Google Scholar
• Malli E, Tatsidou E, Damani A, et al. Macrolide-resistant Streptococcus pyogenes in Central Greece: prevalence; mechanism and molecular identification. Int J Antimicrob Agents 2010;35(6):614-15
   PubMed Web of Science ®Google Scholar
• Grivea IN, Al-Lahham A, Katopodis GD, et al. Resistance to erythromycin and telithromycin in Streptococcus pyogenes isolates obtained between 1999 and 2002 from Greek children with tonsillopharyngitis: phenotypic and genotypic analysis. Antimicrob Agents Chemother 2006;50(1):256-61
   PubMed Web of Science ®Google Scholar
• Syrogiannopoulos GA, Grivea IN, Al-Lahham A, et al. Seven-year surveillance of emm types of pediatric Group A streptococcal pharyngitis isolates in Western Greece. PLoS One 2013;8(8):e71558
   PubMed Web of Science ®Google Scholar
• Creti R, Imperi M, Baldassarri L, et al. emm Types, virulence factors, and antibiotic resistance of invasive Streptococcus pyogenes isolates from Italy: what has changed in 11 years? J Clin Microbiol 2007;45(7):2249-56
   PubMed Web of Science ®Google Scholar
• Montagnani F, Stolzuoli L, Croci L, et al. Erythromycin resistance in Streptococcus pyogenes and macrolide consumption in a central Italian region. Infection 2009;37(4):353-7
   PubMed Web of Science ®Google Scholar
• Melo-Cristino J, Santos L, Silva-Costa C, et al. The Viriato study: update on antimicrobial resistance of microbial pathogens responsible for community-acquired respiratory tract infections in Portugal. Paediatr Drugs 2010;12(Suppl 1):11-17
   PubMedGoogle Scholar
• Silva-Costa C, Pinto FR, Ramirez M, Melo-Cristino J. Decrease in macrolide resistance and clonal instability among Streptococcus pyogenes in Portugal. Clin Microbiol Infect 2008;14(12):1152-9
   PubMed Web of Science ®Google Scholar
• Silva-Costa C, Ramirez M, Melo-Cristino J; the Portuguese Surveillance Group for the Study of Respiratory Pathogens. Rapid inversion of the prevalences of macrolide resistance phenotypes paralleled by a diversification of T and emm types among Streptococcus pyogenes in Portugal. Antimicrob Agents Chemother 2005;49(5):2109-11
   PubMed Web of Science ®Google Scholar
• Friães A, Pinto FR, Silva-Costa C, et al. Group A streptococci clones associated with invasive infections and pharyngitis in Portugal present differences in emm types, superantigen gene content and antimicrobial resistance. BMC Microbiol 2012;12(1):280
   PubMed Web of Science ®Google Scholar
• Friães A, Lopes JP, Melo-Cristino J, et al. Changes in Streptococcus pyogenes causing invasive disease in Portugal: evidence for superantigen gene loss and acquisition. Int J Med Microbiol 2013;303(8):505-13
   PubMed Web of Science ®Google Scholar
• Richter SS, Heilmann KP, Dohrn CL, et al. Increasing telithromycin resistance among Streptococcus pyogenes in Europe. J Antimicrob Chemother 2008;61(3):603-11
   PubMed Web of Science ®Google Scholar
• Meisal R, Andreasson IKG, Hoiby EA, et al. Streptococcus pyogenes isolates causing severe infections in Norway in 2006 to 2007: emm Types, multilocus sequence types, and superantigen profiles. J Clin Microbiol 2010;48(3):842-51
   PubMed Web of Science ®Google Scholar
• Littauer P, Caugant DA, Sangvik M, et al. Macrolide-resistant Streptococcus pyogenes in Norway: population structure and resistance determinants. Antimicrob Agents Chemother 2006;50(5):1896-9
   PubMed Web of Science ®Google Scholar
• Shackcloth J, Williams L, Farrell DJ. Streptococcus pneumoniae and Streptococcus pyogenes isolated from a paediatric population in Great Britain and Ireland: the in vitro activity of telithromycin versus comparators. J Infect 2004;48(3):229-35
   PubMed Web of Science ®Google Scholar
• Bergman M, Huikko S, Pihlajamäki M, et al. Effect of macrolide consumption on erythromycin resistance in Streptococcus pyogenes in Finland in 1997–2001. Clin Infect Dis 2004;38(9):1251-6
   PubMed Web of Science ®Google Scholar
• Siljander T, Lyytikäinen O, Vähäkuopus S, et al. Epidemiology, outcome and emm types of invasive group A streptococcal infections in Finland. Eur J Clin Microbiol Infect Dis 2010;29(10):1229-35
   PubMed Web of Science ®Google Scholar
• Montes M, Tamayo E, Mojica C, et al. What causes decreased erythromycin resistance in Streptococcus pyogenes? Dynamics of four clones in a Southern European region from 2005 to 2012. J Antimicrob Chemother 2014;69(6):1474-82
   PubMed Web of Science ®Google Scholar
• Oliver MA, García-Delafuente C, Cano ME, et al. Rapid decrease in the prevalence of macrolide-resistant group A streptococci due to the appearance of two epidemic clones in Cantabria (Spain). J Antimicrob Chemother 2007;60(2):450-2
   PubMed Web of Science ®Google Scholar
• Petinaki E, Kontos F, Pratti A, et al. Clinical isolates of macrolide-resistant Streptococcus pyogenes in Central Greece. Int J Antimicrob Agents 2003;21(1):67-70
   PubMed Web of Science ®Google Scholar
• Adriaenssens N, Coenen S, Versporten A, et al. European Surveillance of Antimicrobial Consumption (ESAC): outpatient macrolide, lincosamide and streptogramin (MLS) use in Europe (1997-2009). J Antimicrob Chemother 2011;66(Suppl 6):vi37-45
   PubMed Web of Science ®Google Scholar
• Cizman M, Beović B, Seme K, et al. Macrolide resistance rates in respiratory pathogens in Slovenia following reduced macrolide use. Int J Antimicrob Agents 2006;28(6):537-42
   PubMed Web of Science ®Google Scholar
• D’ Humières C, Cohen R, Levy C, et al. Decline in macrolide-resistant Streptococcus pyogenes isolates from French children. Int J Med Microbiol 2012;302(7-8):300-3
   PubMed Web of Science ®Google Scholar
• Van Heirstraeten L, Coenen S, Lammens C, et al. Antimicrobial drug use and macrolide-resistant Streptococcus pyogenes, Belgium. Emerg Infect Dis 2012;18(9):1515-18
   PubMed Web of Science ®Google Scholar
• Farmand S, Henneke P, Hufnagel M, Berner R. Significant decline in the erythromycin resistance of group A streptococcus isolates at a German paediatric tertiary care centre. Eur J Clin Microbiol Infect Dis 2012;31(5):707-10
   PubMed Web of Science ®Google Scholar
• Green M, Martin JM, Barbadora KA, et al. Reemergence of macrolide resistance in pharyngeal isolates of group a streptococci in southwestern Pennsylvania. Antimicrob Agents Chemother 2004;48(2):473-6
   PubMed Web of Science ®Google Scholar
• Martin JM, Green M, Barbadora KA, Wald ER. Erythromycin-resistant group A streptococci in schoolchildren in Pittsburgh. N Engl J Med 2002;346(16):1200-6
   PubMed Web of Science ®Google Scholar
• York MK, Gibbs L, Perdreau-Remington F, Brooks GF. Characterization of antimicrobial resistance in Streptococcus pyogenes isolates from the San Francisco Bay area of northern California. J Clin Microbiol 1999;37(6):1727-31
   PubMed Web of Science ®Google Scholar
• Rodríguez C, Rojas P, Wozniak A, et al. [Resistance phenotypes and genotypes of Streptococcus pyogenes clinical isolates in Chile over a 10-year period]. Rev Med Chil 2011;139(9):1143-9
   PubMed Web of Science ®Google Scholar
• Rubinstein G, Amoroso AM, Bavdaz B, et al. Low macrolide resistance in Streptococcus pyogenes in Southern Argentina. Int J Antimicrob Agents 2005;25(5):450-2
   PubMed Web of Science ®Google Scholar
• Lopardo HA, Hernandez C, Vidal P, et al. Erythromycin-resistant Streptococcus pyogenes in Argentina. Medicina (Mex) 2004;64(2):143-5
   Web of Science ®Google Scholar
• Arêas GP, Schuab RB, Neves FP, Barros RR. Antimicrobial susceptibility patterns, emm type distribution and genetic diversity of Streptococcus pyogenes recovered in Brazil. Mem Inst Oswaldo Cruz 2014;109(7):935-9
   PubMed Web of Science ®Google Scholar
• Liang Y, Shen X, Huang G, et al. Characteristics of Streptococcus pyogenes strains isolated from Chinese children with scarlet fever. Acta Paediatr 97(12):1681-5
   PubMed Web of Science ®Google Scholar
• Tse H, Bao JYJ, Davies MR, et al. Molecular characterization of the 2011 Hong Kong scarlet fever outbreak. J Infect Dis 2012;206(3):341-51
   PubMed Web of Science ®Google Scholar
• Davies MR, Holden MT, Coupland P, et al. Emergence of scarlet fever Streptococcus pyogenes emm12 clones in Hong Kong is associated with toxin acquisition and multidrug resistance. Nat Genet 2015;47(1):84-7
   PubMed Web of Science ®Google Scholar
• Huang C-Y, Lai J-F, Huang I-W, et al. Epidemiology and molecular characterization of macrolide-resistant Streptococcus pyogenes in Taiwan. J Clin Microbiol 2014;52(2):508-16
   PubMed Web of Science ®Google Scholar
• Chen Y-Y, Huang C-T, Yao S-M, et al. Molecular epidemiology of group A streptococcus causing scarlet fever in northern Taiwan, 2001–2002. Diagn Microbiol Infect Dis 2007;58(3):289-95
   PubMed Web of Science ®Google Scholar
• Bae SY, Kim JS, Kwon J-A, et al. Phenotypes and genotypes of macrolide-resistant Streptococcus pyogenes isolated in Seoul, Korea. J Med Microbiol 2007;56(Pt 2):229-35
   PubMed Web of Science ®Google Scholar
• Kim S, Yong Lee N. Antibiotic resistance and genotypic characteristics of group A streptococci associated with acute pharyngitis in Korea. Microb Drug Resist 2004;10(4):300-5
   PubMed Web of Science ®Google Scholar
• Shibl AM. Patterns of macrolide resistance determinants among S. pyogenes and S. pneumoniae isolates in Saudi Arabia. J Int Med Res 2005;33(3):349-55
   PubMed Web of Science ®Google Scholar
• Nir-Paz R, Block C, Shasha D, et al. Macrolide, lincosamide and tetracycline susceptibility and emm characterisation of invasive Streptococcus pyogenes isolates in Israel. Int J Antimicrob Agents 2006;28(4):313-19
   PubMed Web of Science ®Google Scholar
• Sakran W, Raz R, Chazan B, et al. Susceptibility of Streptococcus pyogenes to two macrolides in northern Israel. Int J Antimicrob Agents 2004;23(5):517-19
   PubMed Web of Science ®Google Scholar
• Malhotra-Kumar S, Lammens C, Coenen S, et al. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Lancet 2007;369(9560):482-90
   PubMed Web of Science ®Google Scholar
• Pires R, Rolo D, Morais A, et al. Description of macrolide-resistant and potential virulent clones of Streptococcus pyogenes causing asymptomatic colonization during 2000-2006 in the Lisbon area. Eur J Clin Microbiol Infect Dis 2012;31(5):849-57
   PubMed Web of Science ®Google Scholar
• Szczypa K, Sadowy E, Izdebski R, Hryniewicz W. A rapid increase in macrolide resistance in Streptococcus pyogenes isolated in Poland during 1996-2002. J Antimicrob Chemother 2004;54(4):828-31
   PubMed Web of Science ®Google Scholar
• Reinert RR, Lütticken R, Sutcliffe JA, et al. Clonal relatedness of erythromycin-resistant Streptococcus pyogenes isolates in Germany. Antimicrob Agents Chemother 2004;48(4):1369-73
   PubMed Web of Science ®Google Scholar
• Montes M, Orden B, Tamayo E, et al. Characterisation of the main clones of Streptococcus pyogenes carrying the ermA (subclass TR) gene in Spain. Int J Antimicrob Agents 2006;28(5):408-12
   PubMed Web of Science ®Google Scholar
• Silva-Costa C, Friães A, Ramirez M, Melo-Cristino J. Differences between macrolide resistant and susceptible Streptococcus pyogenes: the importance of clonal properties in addition to antibiotic consumption. Antimicrob Agents Chemother 2012;56(11):5661-6
   PubMed Web of Science ®Google Scholar
• Richter SS, Heilmann KP, Beekmann SE, et al. Macrolide-resistant Streptococcus pyogenes in the United States, 2002-2003. Clin Infect Dis 2005;41(5):599-608
   PubMed Web of Science ®Google Scholar
• Tanz RR, Shulman ST, Shortridge VD, et al. Community-based surveillance in the united states of macrolide-resistant pediatric pharyngeal group A streptococci during 3 respiratory disease seasons. Clin Infect Dis 2004;39(12):1794-801
   PubMed Web of Science ®Google Scholar
• Feng L, Lin H, Ma Y, et al. Macrolide-resistant Streptococcus pyogenes from Chinese pediatric patients in association with Tn916 transposons family over a 16-year period. Diagn Microbiol Infect Dis 2010;67(4):369-75
   PubMed Web of Science ®Google Scholar
• Wajima T, Murayama SY, Sunaoshi K, et al. Distribution of emm type and antibiotic susceptibility of group A streptococci causing invasive and noninvasive disease. J Med Microbiol 2008;57(Pt 11):1383-8
   PubMed Web of Science ®Google Scholar
• Steer AC, Law I, Matatolu L, et al. Global emm type distribution of group A streptococci: systematic review and implications for vaccine development. Lancet Infect Dis 2009;9(10):611-16
   PubMed Web of Science ®Google Scholar
• Willems RJL, Hanage WP, Bessen DE, Feil EJ. Population biology of Gram-positive pathogens: high-risk clones for dissemination of antibiotic resistance. FEMS Microbiol Rev 2011;35(5):872-900
   PubMed Web of Science ®Google Scholar
• Walker MJ, Barnett TC, McArthur JD, et al. Disease manifestations and pathogenic mechanisms of group A Streptococcus. Clin Microbiol Rev 2014;27(2):264-301
   PubMed Web of Science ®Google Scholar
• Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 2014;59(2):e10-52
   PubMed Web of Science ®Google Scholar
• Shulman ST, Bisno AL, Clegg HW, et al. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. Clin Infect Dis 2012;55(10):e86-e102
   PubMed Web of Science ®Google Scholar
• Matthys J, De Meyere M, van Driel ML, De Sutter A. Differences among international pharyngitis guidelines: not just academic. Ann Fam Med 2007;5(5):436-43
   PubMed Web of Science ®Google Scholar
• ESCMID Sore Throat Guideline Group. Pelucchi C, Grigoryan L, et al. Guideline for the management of acute sore throat. Clin Microbiol Infect 2012;18(Suppl 1):1-28
   Google Scholar
• Chiappini E, Regoli M, Bonsignori F, et al. Analysis of different recommendations from international guidelines for the management of acute pharyngitis in adults and children. Clin Ther 2011;33(1):48-58
   PubMed Web of Science ®Google Scholar
• Bisno AL, Gerber MA, Gwaltney JM, et al. Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. Clin Infect Dis 2002;35(2):113-25
   PubMed Web of Science ®Google Scholar
• Agence Française de Sécurité Sanitaire des Produits de Santé. Systemic antibiotic treatment in upper and lower respiratory tract infections: official French guidelines. Clin Microbiol Infect 2003;9(12):1162-78
   PubMed Web of Science ®Google Scholar
• Conseil du médicament Québec. Pharyngitis-tonsillitis in children and adults [Internet]. 2010. Available from: http://www.inesss.qc.ca/fileadmin/doc/CDM/UsageOptimal/Guides-serieI/CdM-Antibio1-PhagyngitisTonsillitis-en.pdf
   Google Scholar
• National Institute for Health and Clinical Excellence (NICE). Respiratory tract infections - antibiotic prescribing. Prescribing of antibiotics for self-limiting respiratory tract infections in adults and children in primary care (clinical guideline 69) [Internet]. 2008. Available from: http://www.nice.org.uk/guidance/cg69
   Google Scholar
• Scottish Intercollegiate Guidelines Network (SIGN). Management of sore throat and indications for tonsillectomy - A national clinical guideline [Internet]. 2010. Available from: http://www.sign.ac.uk/pdf/sign117.pdf
   Google Scholar
• Van Driel ML, De Sutter AIM, Keber N, et al. Different antibiotic treatments for group A streptococcal pharyngitis. Cochrane Database Syst Rev 2013;4:CD004406
   Google Scholar
• Allen U, Moore D. Invasive group A streptococcal disease: management and chemoprophylaxis. Can J Infect Dis Med Microbiol 2010;21(3):115-18
   PubMed Web of Science ®Google Scholar
• Stevens DL, Gibbons AE, Bergstrom R, Winn V. The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis 1988;158(1):23-8
   PubMed Web of Science ®Google Scholar
• Sriskandan S, McKee A, Hall L, Cohen J. Comparative effects of clindamycin and ampicillin on superantigenic activity of Streptococcus pyogenes. J Antimicrob Chemother 1997;40(2):275-7
   PubMed Web of Science ®Google Scholar
• Gemmell CG, Peterson PK, Schmeling D, et al. Potentiation of opsonization and phagocytosis of Streptococcus pyogenes following growth in the presence of clindamycin. J Clin Invest 1981;67(5):1249-56
   PubMed Web of Science ®Google Scholar
• Carapetis JR, Jacoby P, Carville K, et al. Effectiveness of clindamycin and intravenous immunoglobulin, and risk of disease in contacts, in invasive group A streptococcal infections. Clin Infect Dis 2014;59(3):358-65
   PubMed Web of Science ®Google Scholar
• Zimbelman J, Palmer A, Todd J. Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection. Pediatr Infect Dis J 1999;18(12):1096-100
   PubMed Web of Science ®Google Scholar
• Linner A, Darenberg J, Sjolin J, et al. Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: a comparative observational study. Clin Infect Dis 2014;59(6):851-7
   PubMed Web of Science ®Google Scholar
• Sriskandan S, Ferguson M, Elliot V, et al. Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation. J Antimicrob Chemother 2006;58(1):117-24
   PubMed Web of Science ®Google Scholar
• Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005;41(10):1373-406
   PubMed Web of Science ®Google Scholar
• Tan LKK, Sriskandan S. Editorial commentary: step on the GAS: are we almost there for clindamycin and intravenous immunoglobulin? Clin Infect Dis 2014;59(3):366-8
   PubMed Web of Science ®Google Scholar
• Van Asselt GJ, de Kort G, van de Klundert JA. Differences in penicillin-binding protein patterns of penicillin tolerant and non-tolerant group A streptococci. J Antimicrob Chemother 1995;35(1):67-74
   PubMed Web of Science ®Google Scholar
• Katz KC, McGeer AJ, Duncan CL, et al. Emergence of macrolide resistance in throat culture isolates of group a streptococci in Ontario, Canada, in 2001. Antimicrob Agents Chemother 2003;47(7):2370-2
   PubMed Web of Science ®Google Scholar
• Villaseñor-Sierra A, Katahira E, Jaramillo-Valdivia AN, et al. Phenotypes and genotypes of erythromycin-resistant Streptococcus pyogenes strains isolated from invasive and non-invasive infections from Mexico and the USA during 1999-2010. Int J Infect Dis 2012;16(3):e178-81
   Web of Science ®Google Scholar
• Doern GV, Brown SD. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01. J Infect 2004;48(1):56-65
   PubMed Web of Science ®Google Scholar
• Liu X, Shen X, Chang H, et al. High macrolide resistance in Streptococcus pyogenes strains isolated from children with pharyngitis in China. Pediatr Pulmonol 2009;44(5):436-41
   PubMed Web of Science ®Google Scholar
• Ikebe T, Hirasawa K, Suzuki R, et al. Antimicrobial susceptibility survey of Streptococcus pyogenes isolated in Japan from patients with severe invasive group A streptococcal infections. Antimicrob Agents Chemother 2005;49(2):788-90
   PubMed Web of Science ®Google Scholar
• Kobayashi I, Hasegawa M, Kanayama A, et al. Alarming trend of clarithromycin-resistant Streptococcus pyogenes in Japan (1998-2002). J Infect Chemother 2005;11(2):56-8
   PubMedGoogle Scholar
• Wajima T, Morozumi M, Chiba N, et al. Associations of macrolide and fluoroquinolone resistance with molecular typing in Streptococcus pyogenes from invasive infections, 2010–2012. Int J Antimicrob Agents 2013;42(5):447-9
   PubMed Web of Science ®Google Scholar
• Yi YH, Choi JH, Lee HK, et al. Characterization of erythromycin resistance of Streptococcus pyogenes isolated from pharyngitis patients in Korea. Jpn J Infect Dis 2006;59(3):192-4
   PubMed Web of Science ®Google Scholar
• Malhotra-Kumar S, Lammens C, Chapelle S, et al. Macrolide- and telithromycin-resistant Streptococcus pyogenes, Belgium, 1999-2003. Emerg Infect Dis 2005;11(6):939-42
   PubMed Web of Science ®Google Scholar
• Luca-Harari B, Ekelund K, van der Linden M, et al. Clinical and epidemiological aspects of invasive Streptococcus pyogenes infections in Denmark during 2003 and 2004. J Clin Microbiol 2008;46(1):79-86
   PubMed Web of Science ®Google Scholar
• Plainvert C, Doloy A, Loubinoux J, et al. Invasive group A streptococcal infections in adults, France (2006-2010). Clin Microbiol Infect 2012;18(7):702-10
   PubMed Web of Science ®Google Scholar
• Bingen E, Bidet P, Mihaila-Amrouche L, et al. Emergence of macrolide-resistant Streptococcus pyogenes strains in French children. Antimicrob Agents Chemother 2004;48(9):3559-62
   PubMed Web of Science ®Google Scholar
• Imöhl M, Reinert RR, Ocklenburg C, van der Linden M. Epidemiology of invasive Streptococcus pyogenes disease in Germany during 2003-2007. FEMS Immunol Med Microbiol 2010;58:389-96
   PubMedGoogle Scholar
• Reinert RR, Lütticken R, Bryskier A, Al-Lahham A. Macrolide-resistant Streptococcus pneumoniae and Streptococcus pyogenes in the pediatric population in Germany during 2000-2001. Antimicrob Agents Chemother 2003;47(2):489-93
   PubMed Web of Science ®Google Scholar
• Reinert RR, Franken C, van der Linden M, et al. Molecular characterisation of macrolide resistance mechanisms of Streptococcus pneumoniae and Streptococcus pyogenes isolated in Germany, 2002–2003. Int J Antimicrob Agents 2004;24(1):43-7
   PubMed Web of Science ®Google Scholar
• Bley C, van der Linden M, Reinert RR. mef(A) is the predominant macrolide resistance determinant in Streptococcus pneumoniae and Streptococcus pyogenes in Germany. Int J Antimicrob Agents 2011;37(5):425-31
   PubMed Web of Science ®Google Scholar
• Mazzariol A, Koncan R, Vitali LA, Cornaglia G. Activities of 16-membered ring macrolides and telithromycin against different genotypes of erythromycin-susceptible and erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae. J Antimicrob Chemother 2007;59(6):1171-6
   PubMed Web of Science ®Google Scholar
• Szczypa K, Sadowy E, Izdebski R, et al. Group A streptococci from invasive-disease episodes in Poland are remarkably divergent at the molecular level. J Clin Microbiol 2006;44(11):3975-9
   PubMed Web of Science ®Google Scholar
• Skoczyńska A, Kadłubowski M, Waśko I, et al. Resistance patterns of selected respiratory tract pathogens in Poland. Clin Microbiol Infect 2007;13(4):377-83
   PubMed Web of Science ®Google Scholar
• Pavlovic L, Grego E, Sipetic-Grujicic S. Prevalence of macrolide resistance in Streptococcus pyogenes collected in Serbia. Jpn J Infect Dis 2010;63(4):275-6
   PubMed Web of Science ®Google Scholar
• Pérez-Trallero E, García-de-la-Fuente C, García-Rey C, et al. Geographical and ecological analysis of resistance, coresistance, and coupled resistance to antimicrobials in respiratory pathogenic bacteria in Spain. Antimicrob Agents Chemother 2005;49(5):1965-72
   PubMed Web of Science ®Google Scholar